Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Upfront surgery or definitive radiotherapy for p16+ oropharyngeal cancer. A GETTEC multicentric study

Abstract : Background: The aim of this study was to assess the impact of the initial therapeutic strategy on oncologic outcomes in patients with HPV-positive OPSCC. Methods: All p16-positive OPSCCs treated from 2009 to 2014 in 7 centers were retrospectively included and classified according to the therapeutic strategy: surgical strategy (surgery ± adjuvant radiotherapy and chemotherapy) vs. non-surgical strategy (definitive radiotherapy ± chemotherapy). Univariate, multivariate propensity score matching analyses were performed to compare overall (OS), disease-specific (DSS) and recurrence-free survival (RFS). Results: 382 patients were included (surgical group: 144; non-surgical group: 238). Five-year OS, DSS and RFS were 89.2, 96.8 and 83.9% in the surgical group and 84.2, 87.1 and 70.4% in the non-surgical group, respectively. These differences were statistically significant for DSS and RFS after multivariate analysis, but only for RFS after propensity score matching analysis. Conclusion: In p16+ OPSCC patients, upfront surgery results in higher RFS than definitive radiotherapy ± chemotherapy but does not impact OS.
Liste complète des métadonnées

https://hal.umontpellier.fr/hal-03166902
Contributeur : Anthony Herrada Connectez-vous pour contacter le contributeur
Soumis le : jeudi 11 mars 2021 - 15:49:02
Dernière modification le : mercredi 1 juin 2022 - 04:25:22

Identifiants

Citation

Dorian Culié, Renaud Schiappa, Anouchka Modesto, Julien Viotti, Emmanuel Chamorey, et al.. Upfront surgery or definitive radiotherapy for p16+ oropharyngeal cancer. A GETTEC multicentric study. EJSO - European Journal of Surgical Oncology, WB Saunders, 2021, In press, ⟨10.1016/j.ejso.2020.12.011⟩. ⟨hal-03166902⟩

Partager

Métriques

Consultations de la notice

49